Most patients should not stop taking GLP-1 receptor agonists prior to elective surgery, according to updated guidance from ...

These medications, which mimic the GLP-1 bodies naturally make, are also used as appetite suppressants and weight loss tools, sold under names like Ozempic, Rubelsus, Trulicity, Wegovy and more.

You may have heard about — or maybe even experienced — the short-term side effects of Ozempic® — such as nausea, vomiting, ...

Less than a year after Eli Lilly began selling Zepbound, sales for its obesity drug are already more than half those of Novo Nordisk’s Wegovy treatment, helping the New York-listed stock jump 54 ...

The reduction in albuminuria with semaglutide was consistent across most subgroups, including when stratified by baseline ...

The new HCPCS Level II code for “Injection, tocilizumab-aazg (Tyenne), biosimilar, 1 mg” is Q5135. “These CMS designations are important reimbursement milestones for Tyenne because they ease access ...

The rise of Wegovy and other new GLP-1 agonist weight-control drugs may be slashing the number of U.S. patients with commercial health insurance or Medicare Advantage plan coverage who undergo ...

Semaglutide, the main ingredient in the injected GLP-1 drugs Ozempic and Wegovy, is associated with a lower risk of Alzheimer’s disease in people with type 2 diabetes, a new study suggests.

The demand for weight loss operations dropped sharply last year as the number of people opting for anti-obesity drugs such as Wegovy and Saxenda more than doubled, a study published Friday found.

Share on Pinterest Semaglutide, the active ingredient in Ozempic and Wegovy, may also help lower the risk of developing Alzheimer’s disease in people living with type 2 diabetes. damkaz/Getty ...